New use for an existing drug as antiviral agent against SARS-CoV-2 to prevent or/and treat COVID-19

  • Marta from Consejo Superior de Investigaciones Cientificas (CSIC)
  • From Spain
  • Responsive
  • Patents for licensing

Summary of the technology

CSIC has discovered a new use for an existing drug on the market as antiviral agent.
Industrial partners from the pharmaceutical industry are being sought to collaborate through a patent licence agreement.

Consejo Superior de Investigaciones Cientificas (CSIC)

Details of the Technology Offer

These days there is a need for safe and effective antiviral agents with a wide spectrum of anti-viral activity. Since the emergence of a novel coronavirus (SARS-CoV-2) from Wuhan, China, in December 2019, that has caused millions of cases of human infections and huge cases of deaths globally and was declared as a pandemic by World Health Organisation, broad-spectrum antivirals for the treatment of emerging and endemic CoVs are needed.

The virus spreads rapidly from the transmission among human, and the symptoms caused by the virus (abbreviated “COVID-19”) ranges from mild cough and fever to severe pneumonia and potentially life-threatening symptoms. Waiting for the availability of new vaccines, this global emergency has triggered the search for safe and effective pharmacological approaches for eradicating the virus, or at least reducing its effects and hindering the contagion, since, currently there is only one approved therapy to treat SARS-CoV-2 infection. By using a computational approach, the library of FDA approved drugs, already used in humans, has been screened to identify in a quick and efficient way potential antiviral agents against SARS-CoV-2 to be subsequently studied in the corresponding biological studies. In this way, a promising candidate has been found.

Intellectual property status

  • Patent already applied for
  • Patent application number :EP20382736.5

Attached documents

Related Keywords

  • Applications for Health
  • Biological Sciences
  • Medicine, Human Health
  • Biostatistics, Epidemiology
  • Pharmaceutical Products / Drugs
  • Virus, Virology / Antibiotics / Bacteriology
  • Human vaccines
  • Biology / Biotechnology
  • Protecting Man and Environment
  • Infectious Diseases
  • Medical/health
  • Medical Health related
  • Consumer related
  • Industrial Products
  • Other
  • Covid-19
  • antiviral
  • coronavirus
  • sars-cov-2

About Consejo Superior de Investigaciones Cientificas (CSIC)

The CSIC is the largest public research body in Spain. It plays an active role in the science policy of all the autonomous regions through their centres across Spain. CSIC's mission includes: 1) Multidisciplinary scientific and technical research; 2) Scientific and technical advice; 3) Transferring results to the private sector; 4) Contributing to the creation of technology-driven companies; 5) Training specialised personnel; 6) Management of infrastructure and large facilities; 7) Promoting scientific culture. The CSIC is multidisciplinary, carrying out research in almost all fields of knowledge. Its activities encompass basic research all the way through to technological development.
It is the 7th Public research institution at global scale
It is the top 5 European institution by number of actions H2020
11000 people
120 institutes, centres, units
14000 articles published per year
+ 3500 ongoing projects
450 protected technologies
+ 600 PhD Thesis defended per year

Marta García Del Barrio

Never miss an update from Marta García Del Barrio

Create your free account to connect with Marta García Del Barrio and thousands of other innovative organizations and professionals worldwide


Send a request for information
to Marta

About Technology Offers

Technology Offers on Innoget are directly posted
and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.


Need help requesting additional information or have questions regarding this Technology Offer?
Contact Innoget support